Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based VP’ operating in the Therapeutics space. If you think a VP’ is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Ron Alfa
Senior Vice President, Translational Discovery of Recursion Pharmaceuticals
Ron Alfa is Vice President, Discovery and Product at Recursion Pharmaceuticals where he manages scientific product development and external alliances across Recursion’s AI-enabled discovery platform. Ron Alfa’s scientific contributions prior to Recursion span Neurosciences, Metabolism, and Genetics.
Follow Ron Alfa:
About Recursion Pharmaceuticals: Recursion Pharmaceuticals is a digital biology company, developing a drug discovery platform and pipeline with machine learning.
Imran Haque
VP Data Science of Recursion Pharmaceuticals
Imran focuses his research on developing computational methods to go beyond brute empiricism in biology and medicine.He earned a BS in electrical engineering and computer science from UC Berkeley and a PhD in computer science from Stanford University, where his research on large-scale machine learning systems for drug discovery was co-advised by Vijay Pande and Daphne Koller.Following his PhD, Imran served for over five years in roles of increasing responsibility at Counsyl (now Myriad Women’s Health). As VP, Scientific Affairs, he led a research program in both clinical development, analyzing cohorts of hundreds of thousands of individuals to make discoveries in medical and population genetics; and in technology development, designing assays leveraging the ability to customize both chemistry and computation. Subsequently, he was the first chief scientific officer at Freenome, where he built and led an R&D team spanning molecular biology, computational biology, and machine learning to develop non-invasive blood-based screening protocols for early cancer detection.
Follow Imran Haque:
About Recursion Pharmaceuticals: Recursion Pharmaceuticals is a digital biology company, developing a drug discovery platform and pipeline with machine learning.
Barrett Dwyer
VP of Finance of Modern Health
Modern Health VP of Finance Barrett Dwyer brings more than a decade of experience in financial modeling, business development strategy, market assessment, and economic valuation of intellectual property to the company. Before joining Modern Health, he held finance and business operations leadership roles at BreezeLabs (a short-term vehicle lease solution for ride-sharing drivers working for Uber and Lyft), where he spearheaded the company’s acquisition by Ford in 2016. He drove strategy and financial modeling behind the rebranding and repositioning of Breeze to Canvas, a subscription-based auto subsidiary of Ford that bundled maintenance, insurance, and roadside assistance. While at Canvas, he was CFO and head of business operations. Barrett also held the VP of finance and operations role at Fair.com, and spent his early career as an analyst and consultant with The Kenrich Group, Stout Risius Ross, and GreatBridge Consulting. He holds a BBA in finance from George Washington University and a master’s in applied economics from Johns Hopkins University. Barrett lives in San Francisco with his wife and enjoys watching content by Stephen Colbert and Sarah Cooper.
Follow Barrett Dwyer:
About Canvas, Modern Health: Modern Health is a mental well-being platform for innovative companies offering therapy, coaching, and self-guided courses all in one app.
Lorna Henri
VP of Customer Success of Modern Health
Lorna Henri is a global customer success leader with 25+ years of experience at enterprise SaaS startups, software companies, and wireless carriers. Before joining Modern Health, she was the global VP of customer success and support at Mapbox, a mapping platform for developers. Prior to that, she spent three years at AppAnnie, where she was the global VP of customer success and helped the mobile app analytics company achieve dominant market share, securing 90% of the top100 iOS and Android publishers. Lorna was global VP of client services at the SEO SaaS platform BrightEdge, where she was a trusted advisor to Fortune 500 CMOs, delivering a client retention rate of more than 95%. She spent nine years as the top marketing executive at U.S. Communities, responsible for customer acquisition and relationship management. She also held leadership roles at Verizon Wireless and Vodafone. She is a frequent speaker at customer success conferences and received the Gainsight Stellar Customer Success Leader award and the MindTouch Top Customer Success Influencer award. Lorna holds a BS in engineering from Stanford University and an MBA from the Stanford Graduate School of Business. Lorna and her husband live in the East Bay where they raised three sons, several dogs, a cat, and a bunny. When she isn’t meeting with customers, you can find her hiking in the Walnut Creek open space.
Follow Lorna Henri:
About Modern Health: Modern Health is a mental well-being platform for innovative companies offering therapy, coaching, and self-guided courses all in one app.
Hannah Adams Willson
VP of Sales of Modern Health
Hannah Adams Willson serves as vice president of sales at Rainforest QA. Most recently, she was a sales manager and executive at Zenefits and vice president for business development at HelloWallet. Prior to these, Hannah was a director at The Corporate Executive Board (now Gartner). Hannah holds a BA degree from The Johns Hopkins University.
Follow Hannah Adams Willson:
About Modern Health: Modern Health is a mental well-being platform for innovative companies offering therapy, coaching, and self-guided courses all in one app.
Jillian B. Thomsen
SVP Finance and Chief Accounting Officer of Nektar Therapeutics
Follow Jillian B. Thomsen:
About Nektar Therapeutics: Nektar Therapeutics develops therapeutics based on its advanced polymer conjugate chemistry technology platform.
Earl May
Vice President of Lead Discovery of Civetta Therapeutics
Earl May is the Vice President of Lead Discovery at Civetta Therapeutics. He is a former Senior Director Biophysics at Warp Drive Bio, Inc. Mr. May graduated from the University of Maryland Baltimore County with a BA in Biochemistry and received an MPhil and Ph.D.in Molecular Biophysics and Biochemistry at Yale University.
Follow Earl May:
About Civetta Therapeutics: Civetta Therapeutics is a cancer therapeutics company to advance new medicines through small molecule targeting of beta-propeller domains.
Andrew Cook
Vice President and Head of Chemistry of Civetta Therapeutics
Andrew Cook is the Vice President and Head of Chemistry at Civetta Therapeutics. He was an Associate Director and Director of Medicinal Chemistry at H3 Biomedicine. Mr. Cook graduated from Imperial College London with a Ph.D. in Organic Chemistry and earned a BS in Chemistry at the University of Nottingham.
Follow Andrew Cook:
About Civetta Therapeutics: Civetta Therapeutics is a cancer therapeutics company to advance new medicines through small molecule targeting of beta-propeller domains.
Chris Fuller
Vice President of Informatics of Caribou Biosciences
Follow Chris Fuller:
About Caribou Biosciences: Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
Margaret Dowling
VP, Clinical Engagement of Hinge Health
Margaret Dowling, MPH is the VP of Clinical Engagement at Hinge Health.
Follow Margaret Dowling:
About Hinge Health: Hinge Health is a patient-centered digital clinic for treating chronic musculoskeletal conditions.
Christine Lui Chen
VP, Marketing of Hinge Health
Wharton MBA, Johns Hopkins Neuroscience, Product Launch & BD at J&J, pug aficionado.
Follow Christine Lui Chen:
About Hinge Health: Hinge Health is a patient-centered digital clinic for treating chronic musculoskeletal conditions.
Kelvin Kwong
VP of Product Management of Big Health
Kelvin Kwong is the VP Product at Big Health.
Follow Kelvin Kwong:
About Big Health: Big Health is a digital therapeutics company operating a healthcare portal to offer behavioral programs for mental health issues.
Agatha Martindale
Vice President and Global Finance of Rakuten Medical
Follow Agatha Martindale:
About BUILTBYGIRLS, Rakuten Medical, Rakuten Medical: Rakuten Medical is a biotechnology company that develops therapies to treat cancer.
Hyam Levitsky
Executive Vice President Research, Chief Scientific Officer of Juno Therapeutics
Hyam (“Hy”) Levitsky is our Executive Vice President, Chief Scientific Officer and joined Juno in May 2015. Prior to joining Juno, Hyam Levitsky held the position of Head of Cancer Immunology Experimental Medicine at Roche Pharma Research and Development in Basel, Switzerland. Prior to that, Levitsky served as a Professor of Oncology, Medicine and Urology at The Johns Hopkins University School of Medicine, and was also an active staff member in Oncology and Medicine at The Johns Hopkins Hospital. Hyam Levitsky received a B.S. from the University of Pennsylvania School of Engineering and Applied Science and an M.D. from The Johns Hopkins School of Medicine. He trained in Medical Oncology as a Senior Clinical Fellow at Johns Hopkins Oncology Center, rising to full Professor in 2001, and taught in the School of Medicine until 2011. His areas of expertise include Oncology, Immunology, Hematologic Malignances / Bone Marrow Transplantation (serving as Scientific Director of the George Santos Bone Marrow Transplant Program), Cellular and Molecular Medicine, and Pathobiology. Hyam Levitsky is also a founding Executive Committee member of the Cancer Immunotherapy Consortium of the Cancer Research Institute. He was a Stohlman Scholar of the Leukemia and Lymphoma Society of America (LLS) and a member of the American Society for Clinical Investigation (ASCI). He was a founding member of MIATA (Minimal Information About T cell Assays), advises the FDA on cancer immunotherapy issues and serves on the External Scientific Advisory Board of the Pasteur Institute’s Center for Human Immunology, has consulted on a number of industry scientific advisory boards and contributes and provides editorial support to several prestigious cancer, immunology, scientific and medical publications. Hyam Levitsky holds several patents.
Follow Hyam Levitsky:
About Century Therapeutics, Juno Therapeutics: Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.
Chris Lento
Vice President of Commercialization of Pear Therapeutics
Follow Chris Lento:
About Pear Therapeutics: Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.
Keith Patton
VP Software Development of Zerigo Health
Follow Keith Patton:
About Zerigo Health: Clarify Medical is a developer of a handheld medical device used to treat psoriasis, eczema, and vitiligo .
Heow Tan
Vice President of Technical Operations of Collegium Pharmaceutical
Heow Tan has worked in the pharmaceutical industry for 25 years. He joined Collegium Pharmaceutical in 2006. He is responsible for CMC Product Development and Manufacturing activities. His experience in CMC includes working with oral, semi-solid and parenteral products, and successfully taking a product from pre-clinical to FDA and European approval. Prior to Collegium, he worked at Praecis Pharmaceuticals Inc., Waltham, Massachusetts as Vice President of Industrial Operations and Development;, He has also served as the Director of Manufacturing Operations for SciClone Pharmaceuticals Incorporated, San Mateo, California. Heow started his career in the Pharmaceutical industry working for Syntex Laboratories in Palo Alto, California, serving as the Manager of Manufacturing Engineering and Manager of Materials Control. He obtained his M.S. in Engineering from the Ohio State University, Ohio, and his M.B.A. from the University of Santa Clara, California.
Follow Heow Tan:
About Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Alison Fleming
EVP ,Product Development & Chief Technology Officer of Collegium Pharmaceutical
Alison Fleming was appointed Chief Technology Officer in 2017. Alison Fleming first joined Collegium Pharmaceutical in 2002, shortly after completing her Ph.D. in the School of Chemical and Biomolecular Engineering at Cornell University. Prior to joining Collegium, her academic research focused on implantable drug delivery systems for cancer therapy. Alison Fleming is an inventor on several United States Patents and pending patent applications and has authored numerous scientific publications and poster presentations in the field of novel drug delivery systems. In 2001 she was the recipient of the Jorge Heller Journal of Controlled Release Outstanding Paper Award. She received her B.S. degree in Chemical Engineering from the University of Massachusetts, Amherst.
Follow Alison Fleming:
About Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Richard Malamut
EVP & Chief Medical Officer of Collegium Pharmaceutical
Richard Malamut joined Collegium Pharmaceutical in April 2019 as Chief Medical Officer. Most recently, Richard Malamut served as Chief Medical Officer, Head of Research and Development and Senior Vice President for Braeburn Pharmaceuticals. Prior to joining Braeburn, he was Chief Medical Officer at Avanir Pharmaceuticals and was Senior Vice President of Global Clinical Development at Teva Pharmaceuticals Industries Ltd where he was responsible for Pain, Neuropsychiatry, Oncology and New Therapeutic Entities. He also previously held roles of increasing responsibility focusing on early clinical development and translational medicine in neurology and analgesia at Bristol-Myers Squibb and AstraZeneca. Richard Malamut earned his medical degree from Hahnemann University and completed both a residency in neurology and a fellowship in neuromuscular disease. He worked as a board-certified academic and clinical neurologist for 17 years and has more than 50 publications in the fields of pain medicine, neuromuscular disease, autonomic disease and neurodegenerative disease.
Follow Richard Malamut:
About Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Scott Dreyer
EVP & Chief Commercial Officer of Collegium Pharmaceutical
Scott Dreyer was appointed Executive Vice President and Chief Commercial Officer in July 2018. Scott Dreyer joined Collegium in January 2018 as Senior Vice President of Sales, Marketing, Commercial Capabilities and Training. He has over 25 years of commercial experience across sales, marketing, commercial operations and strategic planning, all within the biopharma industry. Most recently, Scott Dreyer was Senior Vice President, Marketing and Commercial Operations for The Medicines Company. Prior to joining The Medicines Company, he was Vice President and Chief Marketing Officer-US at Biogen. Prior to Biogen, Scott Dreyer held various commercial leadership positions of increasing responsibility at Merck & Co including Vice President-US Hospital and Oncology Sales and Commercial Operations, Vice President-US Primary Care Sales, Executive Director US Regional Marketing Leader – Neuroscience, Executive Director Customer Marketing and Solutions, Sr. Director of Strategic Planning and Director of Cardiovascular Marketing. Throughout his career, he has been involved in the commercialization of over 35 products across more than 15 therapeutic areas and launched over 20 products. Scott Dreyer received his B.S. degree in Biology from Messiah College in Grantham, PA.
Follow Scott Dreyer:
About Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Brad Webb
VP of Product of SonderMind
Brad Webb is Vice President of Product at SonderMind.
Follow Brad Webb:
About SonderMind, TaskEasy: SonderMind is a digital health and telehealth company redesigning behavioral health to become more accessible, approachable, and utilized.
Maura McCarthy
VP Corporate Development of Skyhawk Therapeutics
Maura McCarthy co-founded Blu Homes inspired by the opportunity to build beautiful, green homes using transformational technology. Previously she worked for several years in venture capital, investing in traditional prefab building as well as consumer products companies at Ironwood Equity. Maura started her career as an economics analyst under the Greenspan administration at the Fed and then at Professor Michael Porter’s research firm, ICIC, in Boston. Maura is a member of the U.S. Green Building Council and the Renewable Energy Business Network, and has served as a judge for the MIT Enterprise Forum and Ignite Clean Energy competition.
Follow Maura McCarthy:
About Dragonfly Therapeutics, Ignite Clean Energy competition., MIT Enterprise, RenewableEnergyWorld.com, Skyhawk Therapeutics, U.S. Green Building Council (USGBC), Uncommon Productions: Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.
James Hinrichs
Executive Vice President and Chief Financial Officer of Alere
James (“Jim”) Hinrichs joined Alere in April 2015 as Executive Vice President and Chief Financial Officer, with global responsibility for Finance, Accounting, Procurement, IT and Shared Services. Prior to his appointment as CFO of Alere, Jim Hinrichs was CFO at CareFusion Corp., a global medical technology corporation, since 2010. He held this position through the completion of Becton Dickinson’s acquisition of CareFusion in March 2015. Prior to this role, Hinrichs served as SVP of Global Customer Support and, before that, Corporate Controller of CareFusion. Previously, he was Executive Vice president and Controller of Cardinal Health, CFO of Cardinal Health’s Clinical and Medical Products segment and CFO of Cardinal Health’s Healthcare Supply Chain Services segment.. He joined Cardinal Health in February 2004, following 12 years of finance and marketing roles at Merck & Co. and two years as the CFO of SangStat Medical Corporation.
Follow James Hinrichs:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
John Bridgen
SVP, Business Development of Alere
John Bridgen, Ph.D. has served as Senior Vice President, Business Development since July 2010, after serving as our Vice President, Business Development from June 2006 to July 2010. He served as our Vice President, Strategy from September 2005 to June 2006. Dr. Bridgen joined our Company in September 2002, upon our acquisition of Wampole Laboratories, LLC. Dr. Bridgen served as President of Wampole from August 1984 until September 2005. Prior to joining Wampole, Dr. Bridgen had global sales and marketing responsibility for the hematology and immunology business units of Ortho Diagnostic Systems Inc., a Johnson & Johnson company.
Follow John Bridgen:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
Mark Gladwell
Senior Vice President, Global Operations of Alere
Mark Gladwell has served as Senior Vice President, Global Operations since January 2015. From January 2014 through January 2015, he held the role of Vice President, Operations for North America, Europe, Middle East and Africa. From September 2011 through December 2013, Mr. Gladwell served as Vice President of Operations for North America and as President and General Manager of one of Alere’s key manufacturing facilities in North America. From 2007 to 2010 Mr. Gladwell was Vice President, Quality and Technical Service for Alere. From 2005 to 2007, he served as a director covering multiple functions in the start-up of Alere Technology Limited where he focused on the development and manufacture of the Alere home BNP product. Prior to 2005 Mr. Gladwell held a variety of operations, quality and project leadership positions in North America and Europe for Alere, Johnson & Johnson, Agfa Gavert and DuPont. Mr. Gladwell has more than 18 years of experience in manufacturing high-volume, high-technology in-vitro diagnostics and medical devices.
Follow Mark Gladwell:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
Robert Hargadon
VP, Global Human Resources of Alere
Robert Hargadon is the Vice President – Global Human Resources Alere Inc. He joined Alere Inc. as Vice President, Global Culture and Performance in October 2010. He has over 30 years of experience in human resources, leadership and organization development. Mr. Hargadon served as Vice President, Human Resources at drugstore.com, an online pharmacy, from November 2006 through October 2010. Prior to that, Mr. Hargadon was General Manager, Corporate Learning and Development at Microsoft from September 2005 to April 2006 . He held various Human Resources leadership positions at Boston Scientific Corporation, a medical device manufacturer, from 1997 to 2005 , Including Vice President of International Human Resources, Vice President, Leadership Development from September 1997 to June 2005 . Mr. Hargadon also served as Vice President, Learning and Development at Fidelity investments from 1993 to 1997. Mr. Hargadon also has 15 years of experience with the consulting firms Novations Group, Inc. and Harbridge House, which was acquired by PricewaterhouseCoopers LLP.
Follow Robert Hargadon:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
John Ruesch
Vice President of Biogen Idec
John Ruesch is the associate director in QC/Stability/Compliance in the Analytical Research and Development of Pfizer Global Biologics.
Follow John Ruesch:
About Biogen Idec: Biogen Idec is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Tony Polverino
EVP Early Development & CSO of Zymeworks
Anthony (Tony) Polverino, Ph.D., joined Zymeworks in September 2018 and currently serves as our Executive Vice President of Early Development and Chief Scientific Officer. Prior to joining Zymeworks, from 2015 until 2018, Dr. Polverino was at Kite Pharma, Inc., which was acquired by Gilead Sciences, Inc. in 2017. While at Kite he served as the interim Chief Scientific Officer and before that as Vice President of Research. During his tenure, Yescarta®, Kite’s lead chimeric antigen receptor (CAR)-T cell therapy, was approved for relapsed or refractory B cell lymphoma, and multiple programs were advanced to the clinic. Dr. Polverino also assembled an innovative chimeric antigen receptor discovery and development team. Prior to Kite, he was at Amgen Inc. from 1994 to 2014, serving in a number of research leadership roles of increasing responsibility. While at Amgen he managed and advanced numerous research programs utilizing multiple therapeutic modalities, including immunotherapy, oncolytic viruses, bispecific antibodies, antibody-drug conjugates, and small molecules. He also played a key role in the development of over 12 novel antigens for antibody therapeutics. Dr. Polverino earned his undergraduate degree in pharmacology from Adelaide University and his Ph.D. in biochemistry from Flinders University, both in Adelaide, Australia.
Follow Tony Polverino:
About Zymeworks: Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.
Todd Helman
Vice President of Sales of Blockade Medical
Todd is the US National Sales Director at Blockade Medical and has more than 13 years of sales and sales leadership experience working within the medical and interventional neurovascular space. Prior to working at Blockade Medical, Todd held sales leadership roles at Stryker Neurovascular, Concentric Medical and Kyphon Inc. During his time in those positions he successfully recruited, developed and lead teams to multiple annual sales awards. Todd has a rounded experience selling both first to market technologies as well as selling products into more mature and highly competitive product classes. Todd holds a Bachelor of Arts from the University of Maryland and is an avid endurance athlete who competes primarily in Ironman and half Ironman events.
Follow Todd Helman:
About Blockade Medical: Founded in 2011, Blockade Medical is a privately held company dedicated the development of catheter based therapeutic devices for the
Charles Yang
Vice President of Quality Assurance & Regulatory Affairs of Blockade Medical
Charles is currently the Vice President of Quality Assurance and Regulatory Affairs at Blockade Medical. He has been in the medical device industry for over 15 years in the quality and regulatory field with extensive experience in achieving product approvals in a timely manner. Charles has been successful in achieving multiple product approvals through CE Mark, 510K and other regulatory processes all over the world. He has a diversified portfolio of working in start-up companies and large corporations which has allowed him to gain the experience to build efficient quality systems that meet the needs of the medical device industry. Prior to joining Blockade Medical, Charles worked at various medical device companies which include Acutus Medical, MindFrame Inc. (acquired by Covidien), Ablation Frontiers (acquired by Medtronic) and Edwards LifeSciences. Charles received a B.S. in Bio-engineering at the University of California, San Diego.
Follow Charles Yang:
About Blockade Medical: Founded in 2011, Blockade Medical is a privately held company dedicated the development of catheter based therapeutic devices for the
Ryan Solomon
Vice President of Marketing & Business Development of Blockade Medical
Ryan is the Director of Global Marketing and Business Development at Blockade Medical and has more than 10 years of medical sales and marketing expertise including extensive interventional neurovascular experience. Ryan has successfully launched many products in the neurovascular field including launching the first flow diversion device in the United States while serving as the Group Marketing Manager at Covidien Neurovascular and global launches of multiple coil lines as a Sr. Product Manager at MicroVention. His previous roles have also included Associate Marketing Manager at Karl Storz Endoscopy, Sr. Clinical Sales Specialist at Glaxo Smith Kline, and a Professional Sales Representative for Boehringer Ingelheim. Ryan received a B.S. in Business Administration from the University of California, Riverside and a M.B.A. from the University of California, Irvine.
Follow Ryan Solomon:
About Blockade Medical: Founded in 2011, Blockade Medical is a privately held company dedicated the development of catheter based therapeutic devices for the
Roman Yelensky
EVP & CTO of Gritstone Oncology
Roman Yelensky is responsible for overseeing Gritstone’s genomics, proteomics and informatics programs. Previously, he was vice president of biomarker and companion diagnostic development at Foundation Medicine. While there, he co-led sequence data analysis for FoundationOne™ and led validation studies supporting clinical laboratory accreditation and testing of more than 100,000 patients. Roman Yelensky established Foundation Medicine’s FDA-regulated products program, leading to the FDA approval of FoundationFocusCDxBRCA, the first NGS-based companion diagnostic. He also contributed to key national initiatives on the clinical implementation of next-generation sequencing (NGS), leading the diagnostic implementation of Lung-MAP, a first-of-its-kind NCI-sponsored trial matching lung cancer patients to investigational treatments using comprehensive genomic testing. Prior to Foundation Medicine, Roman Yelensky was a senior scientist in biomarker development at Novartis. He has co-authored more than 75 manuscripts on bioinformatics, statistical genetics, NGS biomarker and assay development and cancer genomics. He is an alumnus of Stanford University and the Harvard-MIT Division of Health Sciences and Technology.
Follow Roman Yelensky:
About Gritstone Oncology: Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Shian-Jiun Shih
Vice President of Product Development of Tessa Therapeutics
Dr. Shih has over 20 years of experience in the biopharmaceutical industry, with strong expertise in biological drug development, including cell and gene therapy products and therapeutic proteins, with a focus on immunotherapy. Prior to joining Tessa, she was Director of Molecular Biomarkers and Site Lead of the Translational Medicine and Research Centre, Merck Sharp & Dohme. In that role, her group established non-human primate disease models and developed clinical biomarker assays to support early phase clinical trials, including those for Keytruda. Before that she was Director, Assay Development, Cell Genesys, Inc. She has also held various roles in Bayer, Aventis, and Applied Immune Sciences. Dr. Shih is Founding President of the Chinese Bioscience Association. She holds a Ph.D. in Biochemistry from University of Wisconsin at Madison and completed her post-doctoral training at the School of Medicine, Stanford University.
Follow Shian-Jiun Shih:
About Tessa Therapeutics: Tessa Therapeutics is a provider of therapy designed to focus on T cell therapy for solid tumors.
George Hillman
COO, VP & Co-Founder of Viracta Therapeutics
George Hillman is the Co-Founder, Chief Operating Officer, and Vice President of Viracta Therapeutics.
Follow George Hillman:
About Viracta Therapeutics: Viracta Therapeutics is a precision oncology company focused on new treatment of virus-associated malignancies.
Andrew Scott
Vice President of Corporate Development of Citius Pharmaceuticals
Follow Andrew Scott:
About Citius Pharmaceuticals: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products.
Gary Talarico
Executive Vice President of Operations of Citius Pharmaceuticals
Gary Talarico has served as EVP, Operations since March 2016. Gary has successfully built and led all commercial activities for a number of start-up companies. Most recently he was a founder, partner and Executive Vice President of Leonard Meron Biosciences; he was instrumental in acquiring its lead product. Previously, Gary served as Senior Vice President of Triax Pharmaceuticals, from its founding to the sale of its assets. Gary was a founder and Executive Vice President of Sales and Marketing for Reliant Pharmaceuticals, LLC; Reliant was later sold to GlaxoSmithKline plc. Before Reliant, Gary was Executive Vice President of Business Development for Ventiv Health. His earlier experience included Vice President of Sales for Medicis Pharmaceutical at its initial start-up, and Director of Sales at ICN Pharmaceuticals, Inc. Gary is a graduate of Lewis University.
Follow Gary Talarico:
About Citius Pharmaceuticals: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products.
Alan Lader
Vice President of Clinical Operations of Citius Pharmaceuticals
Alan Lader joined Citius Pharmaceuticals as Vice President of Clinical Operations in 2016
Follow Alan Lader:
About Citius Pharmaceuticals: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products.
Gene DeFelice
Senior Vice President, General Counsel of Adaptive Biotechnologies
Gene DeFelice is an experienced general counsel, chief compliance officer, and corporate secretary with over 30 years of legal experience and over 20 years in healthcare including the diagnostics, biotechnology, pharmaceuticals, and medical device industries. He has served as the General Counsel for several public healthcare and technology companies, and also previously served as the primary counsel for Roche Diagnostics. DeFelice received his Juris Doctorate degree in law from Seton Hall University School of Law and a Masters in Business Administration, with distinction, from Webster University in Geneva, Switzerland. In addition to law, DeFelice has general management experience with full P&L responsibility of a high growth clinical research organization, international sales and marketing leadership, and leadership of FDA regulatory affairs and quality assurance organizations in the life science arena. He has served on the Board of Directors of several private for-profit companies and not-for-profit organizations. DeFelice is a member of the bars of WA, NY, NJ, TX, and DC. Separately, he holds certifications as a Certified Information Privacy Professional- Europe (CIPP-E), a Certified Information Privacy Manager (CIPM), and has been inducted as a Fellow of International Privacy (FIP) by the International Association of Privacy Professionals (IAPP).
Follow Gene DeFelice:
About Adaptive Biotechnologies: Adaptive Biotechnologies translates a scale and precision of the adaptive immune system into products to diagnose and treat disease.
Lori Stewart
VP, People of Adaptive Biotechnologies
Lori Stewart leads the people and talent function at Adaptive, designing and implementing programs and practices that inspire innovation, organizational growth and responsiveness. With over 25 years of human resources expertise across biotechnology, technology and financial services industries, she brings a breadth and depth of expertise and is passionate about the impact human resources has on performance and culture. Prior to joining Adaptive, Stewart held key leadership roles at Zones, Inc., BlackRock, Gilead Sciences and Corus Pharma. She holds an MBA from Northeastern University and lends a global perspective to her leadership from her international experience.
Follow Lori Stewart:
About Adaptive Biotechnologies: Adaptive Biotechnologies translates a scale and precision of the adaptive immune system into products to diagnose and treat disease.
Duane Valz
VP & General Counsel of Insitro
Duane has counseled a wide variety of privately held and public companies on law, technology and business matters. Duane is presently VP & General Counsel of insitro, a company applying machine learning and high throughput biology toward disease target identification and drug discovery. Immediately prior to insitro, Duane was VP & General Counsel at Zymergen, a company applying machine learning and high throughput biology to improving microbial production of in market and novel industrial chemicals. Duane was previously a member of the Patent Team at Google, where he led strategic IP initiatives bearing on mobile, cloud, web and open source technologies. He was also previously Associate General Counsel in charge of patent development at Yahoo! Duane began his career at Howard Rice Nemerovski Canady Falk & Rabkin (now combined with Arnold & Porter LLP). He holds BA and JD degrees from the University of California, Berkeley.
Follow Duane Valz:
About Insitro: Insitro is a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery.
Yalonda Howze
Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary of Codiak Biosciences
Yalonda Howze is the Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary at Codiak BioSciences.
Follow Yalonda Howze:
About Codiak Biosciences: Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.
Michael Zeglinski
SVP and CEO, Optum Specialty and Infusion Pharmacy of BriovaRx
Michael Zeglinski serves as Senior Vice President, Specialty Pharmacy, at OptumRx, the nation’s third-largest pharmacy benefits manager (PBM), and part of Optum, a leading information and technology-enabled health services business. The parent company, UnitedHealth Group (NYSE: UNH), is a diversified health and well-being company, which provides services to more than 120 million people worldwide and includes UnitedHealthcare, the nation’s leading health care provider. Bringing more than 25 years of experience in the pharmacy distribution and specialty pharmaceutical business, including home infusion therapies, Mr. Zeglinski also serves as Chief Executive Officer of Avella and BriovaRx, the OptumRx specialty pharmacies. Both Avella and BriovaRx provide full-service, innovative, patient-centric specialty pharmacy services that serve a diverse customer base, from patients and providers to payers and pharmaceutical manufacturers, with strong focuses in the oncology and limited distribution drug space through 26 specialty pharmacies nationwide. Mr. Zeglinski is responsible for leading the division’s strategy, growth and sales efforts, product development, clinical programs, analytics and outcomes, and operations. In 2015, Mr. Zeglinski joined OptumRx via the acquisition of Catamaran Corporation, a pharmacy benefits management company, where he served as the Senior Vice President of Pharmacy Operations. Prior to Catamaran, he held roles at several of the largest specialty pharmacy organizations, including Quantum Health Resources, Olsten/Gentiva Health Services, Accredo Therapeutics, CVS ProCare, PharmaCare Specialty Pharmacy, and CVS Caremark Specialty. Throughout his career, Mr. Zeglinski developed and implemented numerous pharmacy operating systems and disease-specific care management programs, which focused on increasing patients’ specialty pharmaceutical adherence rates, documenting cost saving interventions and improving quality of life for patients/members. He is also Green Belt certified in Lean Six Sigma processes focusing on the healthcare industry. Mr. Zeglinski holds a Bachelor’s degree in Pharmacy from Duquesne University in Pittsburgh, PA, and pursued his Master’s degree in Fine Arts in Music from Carnegie Mellon University. He is a member of the Academy of Managed Care Pharmacy (AMCP) and the American Pharmacists Association (APhA) and has held licenses in 14 states as a registered pharmacist.
Follow Michael Zeglinski:
About BriovaRx: AxelaCare is a provider of immune globulin and other intravenous home infusion therapies.
Francesca Cook
Vice President, Market Access of REGENXBIO
Francesca Cook is Vice President, Market Accessof REGENXBIO.
Follow Francesca Cook:
About REGENXBIO: REGENXBIO develops adeno-associated viral vector-based therapeutics and research tools, offering NAV, a recombinant AAV-vector.
Michael Klichinsky
Co-Founder & VP, Discovery Research of Carisma Therapeutics
Michael is a PhD Candidate in the Department of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania Perelman School of Medicine.He developed CARMA for his doctoral thesis under the co-mentorship of Saar Gill, MD, PhD and Carl June, MD. Michael previously earned a Doctor of Pharmacy degree from the University of Sciences in Philadelphia, graduating Magna Cum Laude. Michael’s scientific expertise is in the field of genetic engineering and immunology, with a focus on chimeric antigen receptor technologies.
Follow Michael Klichinsky:
About Carisma Therapeutics: Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Shao-Lee Lin
EVP, Head of Research and Development of Horizon Pharma
Lin has served on our Board of Directors since April 2019. Dr. Lin has served as Executive Vice President, Head of Research and Development and Chief Scientific Officer of Horizon Pharma plc, a biopharmaceutical company, since January 2018. Dr. Lin is an immunologist, rheumatologist and allergist with more than 20 years of academic and clinical research experience. Prior to Horizon, Dr. Lin was a corporate officer and Vice President, Therapeutic Areas, Development Excellence and International Development at AbbVie Inc., a pharmaceutical company, from March 2015 to December 2017. In that role, she led immunology, virology, neuroscience and general medicine, across on-market and pipeline compounds as well as international development across all therapeutic areas. Prior to AbbVie, Dr. Lin was Vice President, Inflammation and Respiratory Development at Gilead Sciences, Inc., a biopharmaceutical company, from July 2012 to February 2015. She also held leadership positions in immunology and other therapeutic areas while at Amgen, Inc., a biotechnology company. Dr. Lin received her medical degree and doctorate at the Johns Hopkins University School of Medicine and completed fellowships and post-doctoral work in rheumatology, allergy and immunology at the University of California San Diego and The Scripps Clinic and Research Institute. She received a Bachelor of Science in biochemistry and chemical engineering from Rice University. Dr. Lin has previously been on the faculty of Rockefeller University as a Clinical Scholar and also served as adjunct faculty at Cornell, University of California Los Angeles, Stanford and Northwestern medical schools. We believe that Dr. Lin is qualified to serve as a member of our Board of Directors based on her more than 20 years of academic and clinical research experience across multiple therapeutic areas.
Follow Shao-Lee Lin:
About ACELYRIN, Horizon Pharma: Horizon Therapeutics focuses on the development of prescription drugs for mild to moderate pain relief and arthritis.
Jeffrey Sherman
Executive Vice President, Development, Manufacturing, and Regulatory Affairs, Chief Medical Officer of Horizon Pharma
Dr. Sherman has served as our executive vice president, development, manufacturing, and regulatory affairs, and chief medical officer since June 2011, as our executive vice president, development and regulatory affairs and chief medical officer since our inception in March 2010 and as the executive vice president, development and regulatory affairs and chief medical officer of Horizon Pharma USA since June 2009. From June 2009 through June 2010, Dr. Sherman served as president and board member of the Drug Information Association (DIA), a nonprofit professional association of members who work in government regulatory, academia, patient advocacy and the pharmaceutical and medical device industry. Dr. Sherman isa former president of DIA and serves as DIA liaison to the Clinical Trial Transformation Initiative (CTTI) a public-private partnership founded by the US Food and Drug Administration and Duke University to improve the quality and efficiency of clinical trials. He also serves on the Board of Advisors of the Center for Information and Study on Clinical Research Participation (CISCRP) a nonprofit organization dedicated to educating and informing the public, patients, medical/research communities, the media and policy makers about clinical research and the role each party plays in the process. He is an adjunct assistant professor of medicine at the Northwestern University Feinberg School of Medicine and is a member of a number of professional societies, as well as a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine. From August 2007 through June 2009, Dr. Sherman served as senior vice president of research and development and chief medical officer at IDM Pharma, which was acquired by Takeda in 2009. From June 2007 through August 2007, he served as vice president of clinical science at Takeda Global Research and Development. From September 2000 through June 2007, Dr. Sherman served as chief medical officer and executive vice president at NeoPharm, Inc., a biopharmaceutical company. From October 1992 through August 2000, Dr. Sherman served as director, senior director and executive director of clinical research, and was head of oncology global medical operations at Searle/Pharmacia, or Searle, a pharmaceutical company. Prior to joining Searle, Dr. Sherman worked in clinical pharmacology and clinical research at Bristol-Myers Squibb Company, a biopharmaceutical company. Dr. Sherman received his medical degree from the Rosalind Franklin University/Chicago Medical School. He completed an internal medicine internship, residency and chief medical residency at Northwestern University, as well as fellowship training at the University of California, San Francisco (UCSF). Dr. Sherman was also a research associate at the Howard Hughes Medical Institute at UCSF.
Follow Jeffrey Sherman:
About Horizon Pharma: Horizon Therapeutics focuses on the development of prescription drugs for mild to moderate pain relief and arthritis.
Charles Eyler
Senior Vice President, Finance and Administration and Treasurer of Puma Biotechnology
Mr. Eyler has served as our Senior Vice President, Finance and Administration and Treasurer since the closing of the Merger on October 4, 2011 and, prior to the Merger, served in such capacity at Puma since September 2011. Prior to joining Puma, Mr. Eyler served as Vice President of Finance at Cougar Biotechnology, Inc. from August 2004 until July 2009 when Cougar was acquired by Johnson & Johnson. He also served as the Treasurer of Cougar from April 2006 to July 2009. From July 2009 until March 2010, Mr. Eyler served on the Cougar Integration Committee and oversaw the integration of Cougar’s finance and IT functions with those of Johnson & Johnson. Prior to joining Cougar, Mr. Eyler served as Chief Financial Officer and Chief Operating Officer of Hayes Medical Inc. from March 1999 to January 2004. Mr. Eyler received his B.S. from Drexel University and his M.B.A. from Saint Francis College.
Follow Charles Eyler:
About Puma Biotechnology: Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
Jim Berend
Chief Financial Officer & Executive Vice President of USMD
Jim Berend serves as chief financial officer and executive vice president of USMD Holdings. In his position, Jim oversees all of USMD’s finance functions and activities. Jim has more than 35 years of experience in healthcare finance, having served as a CFO, consultant, auditor and partner at international accounting and consulting firms. He has extensive experience in all aspects of healthcare accounting and finance across the care continuum. Previously, Jim served as CFO and executive vice president of a company operating surgical hospitals in Texas. He was responsible for finance and accounting, centralized billing office, materials management and hospital financial operations.Jim received his Bachelor of Business Administration, with highest honors, from The University of Texas in Austin. He is a licensed CPA in Texas.
Follow Jim Berend:
About USMD: USMD Holdings develops, operates and manages entities that deliver diagnostic, therapeutic and hospital-based health care to patients.
Michelle Speck
Senior Vice President of Human Resources of USMD
Michelle Speck serves as senior vice president of human resources at USMD. She has more than 20 years of experience working in human resources, strategic planning and business development. In her position, Michelle oversees and manages USMD’s human resources team and provides overall direction and strategic planning for all aspects of USMD’s human resource functions, including physician and employee recruitment and retention, compensation and benefits, physician and employee relations, training, management development and organizational culture development. Prior to joining USMD, Michelle served as regional vice president of human resources at University of Pittsburgh Medical Center Health System, a world-renowned health care provider and insurer, based in Pittsburgh, Pa., that operates more than 20 academic, community and specialty hospitals and 400 outpatients sites. During her time at University of Pittsburgh Medical Center Health System, Michelle was responsible for the strategic and day-to-day human resource operations of two healthcare institutions and all related physician entities. Michelle earned her bachelor’s degree in organizational management at Penn State University and her Masters of Business Administration at Indiana University of Pennsylvania.
Follow Michelle Speck:
About USMD: USMD Holdings develops, operates and manages entities that deliver diagnostic, therapeutic and hospital-based health care to patients.
Richard C. Johnston
Chief Physician Officer & Executive Vice President of USMD
Richard C. Johnston, M.D, is board certified by the American Board of Internal Medicine. He is also the executive vice president and chief physician officer of USMD Holdings, Inc. Dr. Johnston graduated from Texas Tech University School of Medicine in 1975 and completed his Internal Medicine residency in 1978 at Austin Breckenridge Hospital. He has been in private practice in the DFW area since 1978. Dr. Johnston served as the first chief of staff at Las Colinas Medical Center, where he now has a full-time internal medicine practice. In 2004, his group joined the Medical Clinic of North Texas, where he has served as President since 2006. Dr. Johnston is a member of the American Medical Group Association’s Leadership Council. Dr. Johnston’s other interests include travel and tropical medicine.
Follow Richard C. Johnston:
About USMD: USMD Holdings develops, operates and manages entities that deliver diagnostic, therapeutic and hospital-based health care to patients.
Steve Goode
Senior Vice President of Sales & Acquisitions of Verus Healthcare
Steve is the Vice President of Sales and brings with him over 14 years of Sales and Sales Management experience. He joins Verus Healthcare from Watermark Medical where he was a Regional Sales Director and helped build the start-up into one of leading home sleep testing companies in the nation in just 3 years. Prior to joining Watermark, Steve was a Director of Sales at Athlon Sports Communications and sold integrated sports marketing programs to Fortune 500 companies, becoming the youngest Partner in the company. Prior to Athlon Sports, Steve spent 5 years with the Southwestern Company and sold books door-to-door while attending college at The Ohio State University.
Follow Steve Goode:
About Sleep8, SnapWorx, Verus Healthcare, Verustat: Verus Healthcare, Inc. is a health care supply company located in Franklin,
Yun-Fei Zhu
Co-Founder & Vice President, Chemistry of Crinetics Pharmaceuticals
Yun-Fei (Frank) Zhu (Vice President, Chemistry) is a Founder of Crinetics Pharmaceuticals. He received his Ph.D. in Organic Chemistry from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in China, and pursued his postdoctoral studies in the laboratory of Professor Murray Goodman in Department of Chemistry, University of California, San Diego. He joined Neurocrine Biosciences in 1997 where he led chemistry efforts on discovery of nonpeptide GnRH antagonists. He was most recently a Director of Chemistry in the Endocrinology and Metabolism group. His research has involved discovery of small molecule inhibitors of several neuropeptide receptors including CRFR2, MCH receptor, and GnRH-R for the treatment of a range of endocrine diseases.
Follow Yun-Fei Zhu:
About Crinetics Pharmaceuticals, Radionetics Oncology: Crinetics is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics.
Stephen F. Betz
Vice President, Biology of Crinetics Pharmaceuticals
Stephen F. Betz (Vice President, Biology) is a Founder of Crinetics Pharmaceuticals. He earned his Ph.D. in Chemistry from the University of North Carolina at Chapel Hill where he studied protein structure and stability. He pursued postdoctoral studies in the laboratory of William DeGrado at the DuPont Merck Pharmaceutical Company where he focused on protein engineering and de novo design. He moved to pharmaceutical discovery in the Research NMR Group at Abbott Laboratories, working on protein structure, structure-guided drug design, assay development, and compound screening in several different therapeutic areas. Subsequently, he led laboratory efforts at GeneFormatics, a biotechnology company founded on protein function annotation and characterization. Most recently, he was Director of Endocrinology and Metabolism at Neurocrine Biosciences working on the discovery and development of GnRH receptor antagonists and nonpeptide modulators of other endocrine targets.
Follow Stephen F. Betz:
About Crinetics Pharmaceuticals: Crinetics is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics.
Eric Tarcha
SVP Translational Development of Kineta
Eric Tarcha serves as the SVP for Translational Development at Kineta.
Follow Eric Tarcha:
About Kineta: Kineta aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas.
Jacques Bouchy
SVP Business Development and Corporate Communications of Kineta
Jacques Bouchy is the SVP for Business Development and Corporate Communications at Kineta.
Follow Jacques Bouchy:
About Kineta: Kineta aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas.
Ken North
SVP, Corporate Development of Kineta
Ken North brings more than 30 years of financing expertise to Kineta from his work in mortgage banking, entrepreneurial business and charitable organizations. In 1998, he launched Seattle Bank as founding CEO and president and helped grow the company to 700 employees with assets of more than $700 million. In 2007, Seattle Bank was recognized nationally for being the most profitable bank in its class in the nation. Ken retired as CEO in 2007 shortly after the bank sold its Reverse Mortgage division to Bank of America, having become the second largest reverse mortgage lender in the country. Prior to that, Mr. North held increasing levels of senior management with Metropolitan Federal Savings, a $750 million financial institution. Ken was responsible for growing the bank by $350 million in deposits. Mr. North is a past president and past Lt. Governor of the Kiwanis Club of Seattle, a Hixson Fellow; past president of the Greater Seattle Chamber of Commerce’s President’s Club and a past Commandant of the Seattle Seafair Commodores. Ken is a former director on the board of First Place School and served as the chair of the Board Affairs Committee.
Follow Ken North:
About Kineta: Kineta aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas.
Andrew Sklawer
Co-Founder and Vice President, Operations of Brickell Biotech
Mr. Sklawer has been involved in a number of development-stage companies and has most recently served as the Director of Operations at Concordia Pharmaceuticals, Inc., an oncology drug development company acquired by Kadmon Corporation in 2011. Prior to joining Concordia, Mr. Sklawer was the Operations Manager at Verid, Inc., a developer of security technology prior to and subsequent to its acquisition by EMC Corporation. Mr. Sklawer holds a B.S. degree in Marketing from the University of Florida and received his M.B.A. from the University of Miami.
Follow Andrew Sklawer:
About Brickell Biotech: Brickell Biotech is focused on the acquisition, development, and commercialization of drug therapies for the treatment of skin diseases.
Christina Kline
Vice President, Marketing of Xeris Pharmaceuticals
Follow Christina Kline:
About Xeris Pharmaceuticals: Xeris Pharmaceuticals is a pharmaceutical company that develops therapies for patients in endocrinology, neurology, and gastroenterology.
Kenneth Johnson
Senior Vice President of Xeris Pharmaceuticals
Dr. Johnson is currently serving as the Senior Vice President, Clinical Development, Regulatory, Quality Assurance & Medical Affairs at Xeris Pharmaceuticals. Dr. Johnson is responsible for leading these efforts to effectively generate high-quality scientific and clinical evidence for Xeris’ products to support product approval, advance clinical education and practice, inform policy and improve health outcomes for patients. Dr. Johnson has more than 25 years of professional experience in the pharmaceutical industry, pharmaceutical benefits management and academia. Dr. Johnson was most recently Executive Director, US Medical Affairs for Hospital Specialty Products at Merck. Previously, Dr. Johnson held senior management positions in Medical Affairs and Outcomes Research at Circassia Pharmaceuticals, Durata Therapeutics, Horizon Pharma, Takeda Pharmaceuticals North America, NeoPharm, Searle/Pharmacia, and Bristol-Myers Squibb. He also served as Vice President, Analytics and Outcomes Research at Caremark, working with Fortune 200 employers and other pharmacy benefit purchasers. Dr. Johnson began his professional career on faculty at the University of Colorado School of Pharmacy with a practice and research focus in therapeutic drug monitoring and clinical pharmacokinetics. Dr. Johnson has established de-novo Medical Affairs and Outcomes Research functions for four emerging biopharmaceutical companies. In addition, he has established and led regional Medical Affairs teams for both large global and emerging biopharmaceutical companies. Throughout his career, Dr. Johnson has consistently been recognized for his leadership, strategic thinking, collaboration, and ability to innovate across a broad range of organizations.
Follow Kenneth Johnson:
About Xeris Pharmaceuticals: Xeris Pharmaceuticals is a pharmaceutical company that develops therapies for patients in endocrinology, neurology, and gastroenterology.
Allison Wey
Senior Vice President of Investor Relations and Corporate Communications of Xeris Pharmaceuticals
Ms. Wey serves as Senior Vice President of Investor Relations and Corporate Communications. She brings over 30 years of experience in investor relations, corporate communications, media relations and investment banking to Xeris. Prior to joining Xeris, Ms. Wey served as Vice President, Investor Relations and Corporate Communications at Regulus Therapeutics, Durata Therapeutics and Par Pharmaceuticals. Prior to these positions, Ms. Wey was VP, Investor Relations at Boron, LePore & Associates, Senior Vice President at Edelman Financial Worldwide, Managing Director, Financial Communications at Hill & Knowlton, and Associate Director, Equity Capital Markets at Bear, Stearns & Co. Inc. Ms. Wey is a graduate of Drake University.
Follow Allison Wey:
About Durata Therapeutics, Xeris Pharmaceuticals: Xeris Pharmaceuticals is a pharmaceutical company that develops therapies for patients in endocrinology, neurology, and gastroenterology.
Anne Marie Cook
Senior Vice President & General Counsel of SAGE Therapeutics
Anne Marie Cook was appointed Senior Vice President, General Counsel and Secretary in December 2011. Ms. Cook was most recently a partner with Boston-based law firm Choate Hall & Stewart LLP (Choate). There she represented life science companies in structuring and negotiating strategic transactions such as joint ventures, collaborations, mergers and acquisitions and intellectual property licenses. She also provided general legal support in connection with the research, development and commercialization of pharmaceutical products. Prior to joining Choate, Ms. Cook was Senior Vice President, Business & Corporate Development, General Counsel at ViaCell, Inc. Prior to that, she was Vice President, Chief Corporate Counsel, at Biogen Idec Inc.
Follow Anne Marie Cook:
About SAGE Therapeutics: SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.
Wen Bo Wang
Senior Vice President, Technical Operations of Fate Therapeutics
Dr. Wen Bo Wang is Senior Vice President, Technical Operations at Fate Therapeutics, overseeing the company’s manufacturing strategies for its pipeline of off-the-shelf cell-based cancer immunotherapy candidates and scaling the Company’s induced pluripotent stem cell iPSC platform to support late-stage clinical and commercial operations. She was formerly Senior Vice President Cell Therapy R&D at Fujifilm Cellular Dynamics Inc (FCDI), where she was responsible for developing the cell therapy R&D strategy and the iPSC based pipeline products and led the next generation production technology development efforts. Previously, she was VP Process Sciences, and directed scale up and scale out platform process development for iPSC based iCell products and MyCell products including automation and bioreactor work. Prior to joining FCDI in 2008, Dr. Wang was Group Leader, Process Sciences, at Geron Corporation, Menlo Park, CA working with embryonic stem cell derived cell therapies and dendritic cell cancer vaccine. From 2001 to 2005, Dr Wang held a number of positions at ViaCell, Boston, MA including Associate Scientific Director, ViaCord Human Umbilical Cord Blood Bank (a subdivision of ViaCell). Dr. Wang serves on the board of directors for Standards Coordinating Body and as US expert at the US Technical Advisory Group (US TAG) for ISO TC/276 Biotechnology. Dr. Wang earned a B.S. in Biology from Ocean University of Qingdao, P.R. China and received her Ph.D. in Biology from Newcastle University, United Kingdom. She conducted post-doctoral training in Cryobiology at Biosciences Research Laboratory, USDA/Agricultural Research Service, Fargo, N.D.
Follow Wen Bo Wang:
About Cellular Dynamics International, Fate Therapeutics: Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Ulrich Ernst
SVP, Technical Operations of Amunix
Follow Ulrich Ernst:
About Amunix: Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics.
Richard Hector
SVP, Senior Legal Counsel of Amunix
Follow Richard Hector:
About Amunix: Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics.
Raul Krauss
Co-Founder & Vice President of Disarm Therapeutics
Follow Raul Krauss:
About Disarm Therapeutics: Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Raul Krauss
Co-Founder & Vice President of Disarm Therapeutics
Follow Raul Krauss:
About Disarm Therapeutics: Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Nick Macris
Vice President, Environment Sector of Precigen
Mr. Macris brings 15 years of business and technical experience in the natural product, industrial and specialty technical industries to Intrexon. Macris joins the company from Marrone Bio Innovations, an early-stage biopesticide company focused on natural product solutions for disease and pest management in plants and aquatic systems where he was Vice President of Business Development. Macris has worked in various roles at several other agricultural and environmental biotech companies, including business development at Purifics ES Inc., corporate development and mergers and acquisitions at FMC Corporation, and corporate level platform development as well as business development activities to establish a biopesticide portfolio at Rohm & Haas. Prior to pursuing his M.B.A., Macris worked in the specialty chemical division and the tape product engineering group at 3M Canada. Macris earned an M.E.Sc. in Chemical and Biochemical Engineering from the University of Western Ontario and an M.B.A. from the Richard Ivey Business School in London, Canada.
Follow Nick Macris:
About Precigen, Purifics ES Inc, Rohm & Haas: Precigen is a life sciences company researching and developing bio-therapeutic control systems to minimize toxicity.
Lubomir (Lubo) Nechev
Senior Vice President CMC Development of Alnylam Pharmaceuticals
Follow Lubomir (Lubo) Nechev:
About Alnylam Pharmaceuticals, Alnylam Pharmaceuticals: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Hyo Min Park
Co-founder & SVP of Business Operations of GenEdit
Hyo Min Park is the Co-founder and SVP of Business Operations of GenEdit.
Follow Hyo Min Park:
About GenEdit: GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.
Hal Sternberg
VP of Reasearch of AgeX Therapeutics
Hal Sternberg, Ph.D., is Vice President of Research. Prior to joining AgeX, Dr. Sternberg was BioTime’s Vice President of Research for over 25 years and was one of the company’s co-founders. Prior to that Dr. Sternberg held various positions at the University of California at Berkeley from 1982 to 1988, where he supervised a team of researchers studying Alzheimer’s Disease. Dr. Sternberg was instrumental in the development of the medical product Hextend, bringing it through regulatory approval as a blood plasma volume expander for the treatment of blood volume loss during routine surgery or emergency trauma surgery. Dr. Sternberg received his M.S. in chemistry in 1979 and Ph.D. in Biochemistry in 1982 from the University of Maryland.
Follow Hal Sternberg:
About AgeX Therapeutics: AgeX is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease.
Frederique Menzaghi
Chief Scientific Officer, Senior VP Research & Development of Cara Therapeutics
Dr. Menzaghi, one of our founders, has served as our Vice President – Research and Development since September 2004 leading our drug discovery programs and clinical operations. Dr. Menzaghi has over 20 years of drug development and management experience in biotechnology in the field of ion channels and GPCRs. Her expertise ranges from early exploratory research through clinical development, She has a successful track record in leading numerous drug discovery programs in the areas of pain, inflammation, obesity, psychiatric, cognitive and neurological disorders and guiding numerous compounds to late Phase 2 clinical trials including one compound approved by FDA in 2013 for the treatment of obesity. She has led or contributed to the filing of numerous INDs and CTAs and has led successful interdisciplinary teams spanning the entire drug development process from the validation of novel receptor targets to novel chemical entity formulated for oral, parenteral or transdermal routes of administration. From 2003-2004, she served as VP Pharmacology and Business Development at Psychogenics Inc., a preclinical central nervous system service provider. From 1099 to 2003, she was the Research Director of In Vivo Pharmacology at Arena Pharmaceuticals (NASDAQ: ARNA). Prior to that, Dr. Menzaghi established and directed a preclinical research laboratory at SIBIA Neurosciences. Her research expertise ranged from the development of small molecules to small peptides. She has extensive experience with corporate partnering with large pharmaceutical companies including Eli Lilly, Merck and J&J. Dr. Menzaghi received her Ph.D. in Neurosciences from the Louis Pasteur University, Strasbourg, France and a M.Sc. in clinical psychology from the University of Nancy. She has over 55 peer-reviewed publications and book chapters, 100 international meeting presentations and is listed as an inventor on numerous patents.
Follow Frederique Menzaghi:
About Cara Therapeutics: Cara Therapeutics is a biotechnology company focused on developing therapeutics to treat diseases associated with pain and inflammation.
John Sabat
Senior Vice President of Global Sales/Marketing and National Accounts of Akorn
John R. Sabat is a Sr.V.P.National Accounts -Trade Relations at Akorn, Inc.
Follow John Sabat:
About Akorn: Akorn is a niche generic pharmaceutical company engaged in the development, manufacture and marketing of multi-source and branded
Mark Silverberg
Executive Vice President of Operations of Global Quality Assurance & Technical Services of Akorn
An accomplished multi-disciplinary executive with 34 years experience, Mark Silverberg joined Akorn in April 2005.Mark Silverberg directs Akorn’s manufacturing operations, global Quality Assurance and Research and Development programming. He is responsible for the company’s drug product formulation, filling and packaging facilities, warehousing and distribution, Quality / Microbiological / R&D laboratories, as well as Regulatory Compliance / Regulatory Affairs and relationship management with FDA and other domestic and international regulatory authorities. Mark Silverberg joined Akorn after a successful, thirty-year career at Abbott Laboratories, where he served at the Director level in several division and corporate level positions – including the Hospital Product Divisions (HPD), Pharmaceutical Products Division (PPD), Abbott Diagnostics Division (ADD) and Corporate Quality Assurance / Regulatory Affairs. He directed divisional and corporate support activities for large volume, small volume injectable products and oral dosage drugs, as well as medical device product lines.He holds a B.S. Biology from Marquette University.
Follow Mark Silverberg:
About Akorn: Akorn is a niche generic pharmaceutical company engaged in the development, manufacture and marketing of multi-source and branded
Sam Boddapati
Senior Vice President of Regulatory Affairs of Akorn
An accomplished professional in the pharmaceutical industry with over 25 years of experience, Dr. Boddapati joined Akorn in July 2004. Sam Boddapati is responsible for filing all regulatory submissions to FDA and obtaining their approvals. During his career in the pharmaceutical industry, Sam Boddapati has filed more than 150 submissions including ANDAs, INDs, and NDAs and played a key role in obtaining FDA approval to market the drugs.Prior to joining Akorn, Sam Boddapati held Senior Management roles at SuperGen, Abraxis BioScience, and American Regent.
Follow Sam Boddapati:
About Akorn: Akorn is a niche generic pharmaceutical company engaged in the development, manufacture and marketing of multi-source and branded
Tim Kanter
Vice President Market Access, Trade and Pricing of Orphazyme
Tim Kanter is the CCO of Prescient Medicine, a company focused on producing tools that target patient outcomes and management in two key areas – medication interaction and medication efficacy –including the validated genetic test designed to predict individual risk of opioid addiction, LifeKit® Predict. Tim has worked for major pharmaceutical and biopharmaceutical companies including Baxalta/Baxter, Novo Nordisk, and ALTANA Pharma in both US and global roles. Most recently, he consulted with a variety of companies in the preparation and launch of new products and initiatives within multiple therapeutic areas. Tim holds a BS from the University of Florida and an MBA from the University of South Florida.
Follow Tim Kanter:
About Orphazyme: Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disorders called lysosomal storage diseases.
Monique M. Greer
Vice President, Corporate Communications of Seattle Genetics
Monique Greer now joined in 2018 as Vice President, Corporate Communications. Monique M. Greer joined CTI in November 2012 as Senior Vice President, Corporate Communications and Investor Relations. Greer leads CTI’s global communications to media, investor, patient and employee audiences. Her expertise includes corporate communications, investor and media relations, and advocacy relations in support of product development, commercialization and strategic initiatives. Greer has more than 17 years’ strategic communications experience in the biopharmaceutical industry. Most recently, she was Vice President of Corporate Communications and Investor Relations at Allos Therapeutics, Inc., a commercial-stage hematology/oncology biopharmaceutical company acquired by Spectrum Pharmaceuticals in September 2012. Previously, she served as Senior Associate in the Corporate Communications and Investor Relations San Francisco practice for WCG, a global communications agency. Greer also has served as Senior Director, Corporate Communications and Investor Relations for Dendreon Corporation, as well as Director, Corporate Communications for Heska Corporation. Greer received a bachelor of science in Business Administration from Northeastern University, Boston.
Follow Monique M. Greer:
About Seattle Genetics: Seagen is dedicated to improving patient outcomes with advanced antibody-drug conjugate technology.
Vaughn Himes
EVP, Process Sciences and Technical Operations of Seattle Genetics
Vaughn Himes joined Seattle Genetics in April 2009, bringing more than twenty years of experience in manufacturing, technical operations, process development and scale-up activities. As Executive Vice President, Process Sciences and Technical Operations, he oversees Seattle Genetics’ manufacturing, supply chain and quality assurance and control functions. Previously, Dr. Himes was with Zymogenetics, most recently as Senior Vice President, Technical Operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development. While at Zymogenetics, he oversaw the chemistry, manufacturing and control (CMC) portion of the successful BLA for Recothrom and managed its commercial supply. Previously, he held Vice President positions in manufacturing and development at Corixa, Targeted Genetics and Genovo. Dr. Himes received a B.A. in Chemistry from Pomona College and a Ph.D. in Chemical Engineering from the University of Minnesota.
Follow Vaughn Himes:
About SEAGEN, Seattle Genetics: Seagen is dedicated to improving patient outcomes with advanced antibody-drug conjugate technology.
Christopher Pawlowicz
SVP, Human Resources of Seattle Genetics
Follow Christopher Pawlowicz:
About Seattle Genetics: Seagen is dedicated to improving patient outcomes with advanced antibody-drug conjugate technology.
Andrew Mazar
Co-Founder and Executive Vice President, Research and Development, and Chief Scientific Officer of Monopar
Andrew Mazar, Ph.D. is the Founder and Head of Product Development at Lung Therapeutics, Inc. Andrew serves as Head of Product Development in addition to his current position as Director of the Center for Developmental Therapeutics and Entrepreneur-in-Residence at Northwestern University. Andrew is recognized internationally for his work on the urokinase plasminogen activator (uPA) system and its role in tumor progression. In addition to his research work on the uPA system, Andrew is a veteran of drug discovery having led various oncology drugs from basic research through phase II clinical trials. Prior to Tactic Pharmaceuticals, Andrew was Chief Scientific Officer at Attenuon, where he led the development of three drug projects from discovery into human clinical trials. Andrew was also the Vice President of Biology at Ångstrom Pharmaceuticals, Inc., where he discovered the anti-angiogenic peptide Å6, which is currently being evaluated in phase II trials in oncology. Andrew also discovered a novel uPA receptor-targeting peptide Å17, which was licensed to Diatide/Schering AG. Prior to Ångstrom, Andrew spent over seven years at Abbott Laboratories, where he initiated two anti-angiogenesis pilot projects and was involved in the pre-clinicaldevelopment of two biologic agents that went through Phase III trials. Andrew is also the co-inventor on twelve issued patents, forty pending patent applications, ninety-six full publications in refereed scientific journals, and eight book chapters including reviews on the uPA system, mouse tumor models and the therapeutic targeting of cancer. Andrew received his Ph.D. in Biochemistry from the University of Illinois College of Medicine.
Follow Andrew Mazar:
About Actuate Therapeutics, Lung Therapeutics, Monopar, Northwestern University, Tactic Pharma LLC: Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.
Dirk Hoyns
Co-founder & Vice President of Product Development of Advanced Catheter Therapies
Dirk brings 20+ years of successful product development & commercialization experience in the medical device and biotechnology fields to Advanced Catheter Therapies. Dirk is president of Device Technologies, Inc. a medical device design consultancy and incubator. Since the company’s inception in 2001, he has helped numerous early-stage medical technology companies with their product development activities. His prior experience includes serving as staff engineer and patent officer with the Peripheral Technologies Division of C.R. Bard, where he led multi-disciplinary teams developing products for the interventional radiology & peripheral vascular markets, and with Sepracor, Inc. developing manufacturing of their membrane bioreactor program. Dirk holds and has pending numerous U.S. patents in the fields of peripheral vascular, cardiology, biopsy, orthopedics and other minimally invasive and catheter-based technologies. Dirk is a graduate of Boston’s Wentworth Institute of Technology, with degrees in both Mechanical Design and Management Engineering.
Follow Dirk Hoyns:
About Advanced Catheter Therapies: Advanced Catheter Therapies develops catheter technologies targeting vascular disease including thrombosis, inflammation, and occlusions.
Kevin Dye
VP Finance , Operations and Director of Advanced Catheter Therapies
Kevin is the CEO and owner of The Dye Group, Inc., a senior management business consulting business focused within the medical device industry. He has 31 years of experience in the industry. Prior to his current position he worked as the President of TEFTEC Corporation, a power wheelchair manufacturer; CEO of GenPhar, Inc., a biotech vaccine company; President of SwampCat, an insecticide repellent start up; and Alphamed, Incorporated, a company that developed and manufactured ambulatory infusion pumps. Kevin spent 22 years working at C.R. Bard, Inc. Beginning in Accounting, he worked his way up to Controller of Productos Para el Cuidado de la Salud, S.A. de C.V., a Nogales, Sonora, Mexico maquilladora. Halfway through his time at Bard, he switched careers and became Operations Manager for Bard’s all-silicone catheter manufacturing facility in Tucson, AZ. He then worked in supply chain management, becoming the Director of Global Logistics for Bard’s Peripheral Technologies Division in Covington, GA. Kevin has a BS in Accounting/Finance from Fairleigh Dickinson University – Madison, NJ.
Follow Kevin Dye:
About Advanced Catheter Therapies: Advanced Catheter Therapies develops catheter technologies targeting vascular disease including thrombosis, inflammation, and occlusions.
Michael Briskin
Vice President of Research of Jounce Therapeutics
Follow Michael Briskin:
About Jounce Therapeutics, Phenomic AI: Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
John Mulcahy
Vice President, Research of SiteOne Therapeutics
John Mulcahy PhD, is a Co-Founder and Vice President of Research at SiteOne. As a postdoctoral fellow and graduate student at Stanford, he developed methods for preparing a family of rare, naturally occurring sodium ion channel pore blockers from simple starting materials. He received his A.B. degree from Harvard University, with concentrations in Chemistry, Physics, and the Classics. Honors include a Stanford Dean’s Postdoctoral Fellowship, a National Science Foundation Predoctoral Fellowship, a Pfizer Summer Research Fellowship and a National Merit Scholarship. Dr. Mulcahy is also a Principal Investigator on multiple small business grants awarded to SiteOne by The National Institutes of Health.
Follow John Mulcahy:
About SiteOne Therapeutics, StartX (Stanford-StartX Fund): SiteOne Therapeutics is a San Francisco-based company that develops novel therapeutics and diagnostics.
Ellen Chiniara
Executive Vice President, General Counsel and Corporate Secretary of Alexion Pharmaceuticals
Follow Ellen Chiniara:
About Alexion Pharmaceuticals: Alexion Pharmaceuticals is a biopharmaceutical company that engages in the development and commercialization of mid-to-late-stage therapies.
Weston Daniel
Vice President of Translational Research of Exicure
Weston Daniel is the Vice President of Translational Research at Exicure.
Follow Weston Daniel:
About Exicure: Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.
Mark Jones
Vice President of Engineering of Mevion Medical Systems
Bringing multidiscipline engineering expertise, Mark joined Mevion in 2006 serving as Lead Mechanical Engineer of the magnet and RF accelerator systems and subsequently as Mechanical Engineering Director since 2007. With more than 27 years of experience, Mark has led the development of numerous successful medical equipment products. Mark’s innovative designs have earned him 5 patents while developing MRI and CT imaging products at Analogic Corporation, cardiac imaging products at XRE Corporation, and most recently genetic research and molecular diagnostics products at Affymetrix. Mark holds a B.S. Mechanical Engineering degree from Norwich University as well as a M.S. Engineering Management degree from the Gordon Institute of Tufts University.
Follow Mark Jones:
About Mevion Medical Systems: Mevion Medical Systems develops radiation therapies for the treatment of cancer.
Stanley Rosenthal
Vice President Clinical Systems of Mevion Medical Systems
Skip joined Mevion Medical Systems from The Northeast Proton Therapy Center at Massachusetts General Hospital, where he was Senior Medical Physicist. He has worked there and at the Harvard Cyclotron Laboratory as a medical physicist in radiation oncology and proton therapy for sixteen years.
Follow Stanley Rosenthal:
About Mevion Medical Systems: Mevion Medical Systems develops radiation therapies for the treatment of cancer.
Mark O’Neil-Johnson
Vice President, Analytical Chemistry of Sequoia Sciences
Mark O’Neil-Johnson has over 20 years of experience in the field of NMR spectroscopy and application development of NMR to chemical characterization. Mark began his career as a natural products chemist, performing total synthesis of natural products under Professor John McMurry at the University of California, Santa Cruz. His industrial work began at IBM Research, where he worked as a synthetic chemist at the IBM San Jose research site. Mark joined IBM Instruments in its inception, starting up the San Jose NMR Demo Lab under the direction of Dr. Charles Wade. In 1987, when IBM exited the analytical instruments business, Mark joined Bruker Instruments, setting up the West Coast NMR Demo facility in the San Jose area. While at Bruker Instruments, Mark’s activities included demonstrating NMR at 300, 400 and 500 MHz; leading on-site user training at over 250 customer sites and in-house NMR training courses; developing and demonstrating flow NMR and LC-NMR-MS capabilities and developing NMR applications with scientific collaborators. After joining Sequoia in its inception as a scientific co-founder, Mark built Sequoia’s advanced analytical capabilities for the structure characterization group. He successfully negotiated collaborations with Bruker BioSpin and Protasis, the CapNMR probe company. These collaborations resulted in state-of-the-art small volume NMR research by Sequoia, pushing the frontiers of structure elucidation to the microgram scales. His work in the natural products scientific community has touched many areas. Since 2001 Mark has been presenting Sequoia’s research at scientific conferences in the US, Europe, Asia, and the Middle East. He has been Issue Editor for the special editions of Planta Medica, a leading international journal for natural products research, that have covered the 2012, 2013, and 2014 annual meetings of the American Society of Pharmacognosy (ASP). Mark was the Co-Chair for the 2013 ASP meeting in St. Louis, MO. In conjunction with the ASP meetings, Mark has been teaching an application workshop focused on handling small amounts of material for NMR spectroscopy for the last 3 years. Mark is currently an Editor for Planta Medica Letters.
Follow Mark O’Neil-Johnson:
About Sequoia Sciences: Sequoia Sciences is a pharmaceutical company discovering and developing new medicines for the treatment of bacterial infections and cancers.
Kathy O’Shaughnessy
VP, Regulatory/QA of RefleXion Medical
Follow Kathy O’Shaughnessy:
About RefleXion Medical: RefleXion Medical is a developer of biologically-guided radiotherapy systems for patients with cancer.
Patrick Kleyn
Vice President, Translational R&D and Alliances of Rhythm Pharmaceuticals
Follow Patrick Kleyn:
About Rhythm Pharmaceuticals: Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Irene Aquino
Vice President, Patient Advocacy and Customer Engagement of Rhythm Pharmaceuticals
Follow Irene Aquino:
About Rhythm Pharmaceuticals: Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Carrie Brodmerkel
Vice President Exploratory Biology and Scientific Strategy Janssen Biotherapeutics of Janssen Belgium
Follow Carrie Brodmerkel:
About Janssen Belgium: Janssen Belgium is a pharmaceutical company providing medicines for an array of health concerns in several therapeutic areas.
Sujit Basu
Vice President and Head of Drug, Device and Combination Product Development of Shire
Follow Sujit Basu:
About Shire: Shire biotechnology company that focuses on serving people with rare diseases.
Gabriele Ricci
VP Head of Digital Health and Emerging Technology of Shire
Follow Gabriele Ricci:
About Shire: Shire biotechnology company that focuses on serving people with rare diseases.
Howard Mayer
SVP & Head of Global Clinical Development of Shire
Howard Mayer, MD, is Senior VP & Head-Global Clinical Development at Shire Plc. He is on the Board of Directors at Genocea Biosciences, Inc.
Follow Howard Mayer:
About Shire: Shire biotechnology company that focuses on serving people with rare diseases.
Jeremy Chadwick
Group VP Clinical Development Operations of Shire
Follow Jeremy Chadwick:
About Shire: Shire biotechnology company that focuses on serving people with rare diseases.
Michael Heartlein
Vice President, Research of Shire
Follow Michael Heartlein:
About Shire: Shire biotechnology company that focuses on serving people with rare diseases.
Michael Heartlein
Vice President, Research of Shire
Follow Michael Heartlein:
About Shire: Shire biotechnology company that focuses on serving people with rare diseases.
Naomi Hunder
Senior Vice President of Clinical Research and Development of Silverback Therapeutics
Naomi Hunder is the Senior Vice President of Clinical Research and Development at Silverback Therapeutics.
Follow Naomi Hunder:
About Silverback Therapeutics: Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways.
Peter Baum
VP of Immunology of Silverback Therapeutics
Peter Baum is the VP of Immunology at Silverback Therapeutics.
Follow Peter Baum:
About Silverback Therapeutics: Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways.
Patricia Leith
Vice President of Program Management and Operations of Silverback Therapeutics
Patricia Leith is the Vice President of Program Management and Operations at Silverback Therapeutics.
Follow Patricia Leith:
About Silverback Therapeutics: Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways.
